SynthesisTransfusion2020
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis.
Synthesis in Transfusion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Therapeutic Leukapheresis: Experience of a Single Oncologic Centre.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Pooled it
- Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.Transplantation and cellular therapy · 2021Pooled it
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.Transplantation and cellular therapy · 2021Pooled it
- Disease Subtype and Procedural Determinants of Leukapheresis Efficacy: A Retrospective Single-Center Study.Journal of clinical medicine · 2026Article
- Seizures and Hyperleukocytosis Revealing New-Onset Acute Myeloid Leukemia During Acute COVID-19 Infection.Cureus · 2026Article
- Multiple Organ Failure Due to Leukostasis Caused by Rapidly Progressive Hyperleukocytosis: A Case Report.Cureus · 2025Article
- A young adult patient with Philadelphia positive acute lymphoblastic leukemia presenting with extreme hyperleukocytosis.Clinical case reports · 2025Article
- Emergencies in Hematology: Why, When and How I Treat?Journal of clinical medicine · 2024Review
- Hyperleukocytosis in Pediatric Patients with Acute Lymphoblastic Leukemia: Demographic and Clinical Characteristics.Journal of clinical medicine · 2024Article
- Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario.Current oncology (Toronto, Ont.) · 2024Article
- Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.Blood · 2024Article
- T-cell Acute Lymphoblastic Leukemia in Crisis: Hyperleukocytosis, Tumor Lysis Syndrome, and Innovative Approaches.Cureus · 2024Article
- Complete elimination of hyperleukocytosis risk in AML through early high-quality disease remission.Frontiers in oncology · 2024Article
- Analysis of early and treatment related deaths among children and adolescents with acute myeloid leukemia in Poland: 2005-2023.Frontiers in pediatrics · 2024Article
- Case Report: A case of infantile acute hyperleukocytic leukemia treated by leukapheresis.Frontiers in pediatrics · 2024Article
- Article
- Acute vision loss due to CML leukemic retinopathy reversed with leukapheresis.Clinical case reports · 2023Article
- Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.American journal of hematology · 2022Article
- Leukapheresis in Pediatric Acute Leukemia with Hyperleukocytosis: A Single-Center Experience.Children (Basel, Switzerland) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundUp to 20% of patients with acute myeloid leukemia (AML) present with hyperleukocytosis, usually defined as a white blood cell (WBC) count greater than 100 × 10 STUDY DESIGN AND
methodsFor this systematic review and meta-analysis we searched MEDLINE and EMBASE via Ovid, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science from inception through March 2020 for multiarm studies comparing early mortality rates of patients with AML treated with leukapheresis and those who were not. The risk ratio (RR) of early death for patients who received leukapheresis vs patients who did not was estimated using a sum of the log-ratio of individual study estimates weighted by sample size.
resultsAmong 13 two-arm, retrospective studies with 1743 patients (486 leukapheresis and 1257 nonleukapheresis patients), leukapheresis did not improve the primary outcome of early mortality compared to treatment strategies in which leukapheresis was not used (RR, 0.88; 95% confidence interval [CI], 0.69-1.13; P = .321) without statistically significant heterogeneity between studies (Cochran's Q, 18; P = .115; I
conclusionAs we did not find evidence of a short-term mortality benefit and considering the associated complications and logistic burden, our results argue against the routine use of leukapheresis for hyperleukocytosis among patients with AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.